» Articles » PMID: 39102578

Revisiting Childhood-Onset Systemic Lupus Erythematosus

Overview
Publisher Aves
Specialty Pediatrics
Date 2024 Aug 5
PMID 39102578
Authors
Affiliations
Soon will be listed here.
Abstract

Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune disease with a multisystemic involvement diagnosed during childhood. The disease is marked by the production of autoantibodies targeting self-antigens, often before symptoms emerge. The presentation, clinical course, and outcome vary significantly among patients with cSLE. The onset of cSLE can be at any age during childhood while a diagnosis of cSLE before the age of 5 years is rare and raises a suspicion of monogenic lupus. Childhood-onset systemic lupus erythematosus affects various organs and systems, most frequently presenting with mucocutaneous, musculoskeletal, renal, and neuropsychiatric manifestations. Multiple disease flares can be seen during the disease course. Childhood-onset systemic lupus erythematosus causes significant morbidity and mortality. Children and adolescents with cSLE show higher disease activity and damage, and more aggressive immunosuppressive treatments are needed compared to adultonset SLE. Early diagnosis can be difficult due to the insidious onset with nonspecific symptoms. Disease activity and damage measures aim to ensure an accurate evaluation of disease status. A multidisciplinary approach and individualized disease management are important. Disease management is complex including the control of disease activity, the reduction of flares and damage, and a limitation of drug toxicity while improving the health-related quality of life in patients with cSLE.

Citing Articles

The added value of coupling anti-dsDNA and anti-chromatin antibodies in follow-up monitoring of systemic lupus erythematosus patients.

Carle C, Fortenfant F, Bost C, Belliere J, Faguer S, Chauveau D J Transl Autoimmun. 2025; 10:100274.

PMID: 39917317 PMC: 11799958. DOI: 10.1016/j.jtauto.2025.100274.


The role of UV-induced cutaneous matrix metalloproteinases and mi-RNAs in the pathogenesis of lupus erythematosus.

Ivanova I, Svilenska T, Maisch T, Karrer S, Niebel D, Berneburg M J Transl Autoimmun. 2025; 10():100265.

PMID: 39835284 PMC: 11743922. DOI: 10.1016/j.jtauto.2024.100265.


Transition of patients with systemic lupus erythematosus from pediatric to adult-oriented rheumatology care.

Sener S, Yardimci G, Batu E, Kilic L, Kaya Akca U, Kasap Cuceoglu M Turk J Med Sci. 2024; 54(6):1198-1204.

PMID: 39734331 PMC: 11673664. DOI: 10.55730/1300-0144.5900.


Increased serum human epididymis protein 4 is associated with disease activity and systemic involvement in pediatric-onset systemic lupus erythematosus.

Liu C, Yan L, Zhang M, Duan Y, Luo J, Liu Z Front Immunol. 2024; 15:1461987.

PMID: 39318632 PMC: 11419971. DOI: 10.3389/fimmu.2024.1461987.

References
1.
Avar Aydin P, Shan J, Brunner H, Mitsnefes M . Blood pressure control over time in childhood-onset systemic lupus erythematous. Lupus. 2018; 27(4):657-664. DOI: 10.1177/0961203317751061. View

2.
Silva C, Avcin T, Brunner H . Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken). 2012; 64(12):1787-93. PMC: 3463746. DOI: 10.1002/acr.21757. View

3.
Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

4.
Binder E, Edelbauer M . Use of biomarkers in the management of children with lupus. Curr Rheumatol Rep. 2013; 15(3):312. DOI: 10.1007/s11926-012-0312-0. View

5.
Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View